Drug intelligence / Profile preview

miR-29a-5p mimic

Development stage
Preclinical
Lead developer
Viridian Therapeutics
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Inhalation, Subcutaneous
01

Overview

miR-29a-5p mimic is a synthetic double-stranded RNA molecule designed to replicate the biological activity of the endogenous microRNA miR-29a-5p. In the context of oncology research, particularly prostate cancer, miR-29a-5p has been identified as a key regulator of ferroptosis, an iron-dependent form of regulated cell death. The mimic functions by binding to the 3' untranslated region (UTR) of target messenger RNAs, such as Ferritin Heavy Chain 1 (FTH1), leading to their translational repression or degradation. Research indicates that miR-29a-5p overexpression (via mimics) inhibits ferroptosis by reducing intracellular labile iron (Fe2+) and lipid peroxidation (MDA) levels, thereby promoting tumor cell survival and proliferation. Conversely, the suppression of miR-29a-5p has been shown to inhibit tumor growth in vivo, suggesting that the miR-29a-5p/FTH1 axis is a potential therapeutic target for inducing ferroptosis in cancer cells.

Other names
hsa-miR-29a-5p mimichsa-miR29a-5p mimichsa-miR 29a-5p mimicmicroRNA-29a-5p mimicmicroRNA29a-5p mimicmicroRNA 29a-5p mimic
02

Targets

FTH1 (Ferritin heavy chain 1)

Beyond the preview

Go deeper on miR-29a-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-29a-5p mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call